Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Wake Forest University Health Sciences
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Virginia Commonwealth University
Sun Yat-sen University
Weill Medical College of Cornell University
Seagen Inc.
Shanghai Pulmonary Hospital, Shanghai, China
Shanghai Pulmonary Hospital, Shanghai, China
National Cancer Institute (NCI)
McGill University Health Centre/Research Institute of the McGill University Health Centre
National Cancer Institute (NCI)
BioNTech SE
Emory University
Merck Sharp & Dohme LLC
Peking University Cancer Hospital & Institute
Mayo Clinic
M.D. Anderson Cancer Center
BeOne Medicines
Bristol-Myers Squibb
Swiss Cancer Institute
Jiangsu Cancer Institute & Hospital
Institut Claudius Regaud
M.D. Anderson Cancer Center
AbbVie
AbbVie
Danish Gynecological Cancer Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Janssen Research & Development, LLC
National Cancer Institute (NCI)
AstraZeneca
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
University of Pittsburgh
National Cancer Institute (NCI)
University of Chicago
Eastern Cooperative Oncology Group
Jiangsu HengRui Medicine Co., Ltd.
University of Washington
National Cancer Institute (NCI)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Hoosier Cancer Research Network